The Latest Cardiac and Vascular News
Cardiovascular industry veteran will help propel Elucid’s next generation AI-powered software to the forefront of disease risk prediction and management BOSTON–(BUSINESS WIRE)–Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Scott Burger as chief commercial officer. […]
GENEVA, Jan. 25, 2023 /PRNewswire/ — The first US patient has been enrolled at MedStar Washington Hospital Center in the SELUTION4ISR study evaluating SELUTION SLR™ to support FDA approval. This milestone follows Investigational Device Exemption (IDE) approval in the US in October 2022. SELUTION SLR is the first sustained limus release coronary drug-eluting balloon […]
Cardiovascular Disease is the Number One Cause of Death Nationwide WASHINGTON, Jan. 25, 2023 /PRNewswire/ — The number of cardiovascular deaths is on the rise again after a decades-long decline. As organizations working to advance cardiovascular health and the interests of medically underserved communities, the Foundation of the National Lipid Association and the […]
Fourth-quarter sales of $10.1 billion; full-year 2022 sales of $43.7 billion Full-year 2022 sales growth of 1.3 percent; organic sales growth of 6.4 percent Full-year 2022 GAAP diluted EPS of $3.91; adjusted diluted EPS of $5.34 Continues to strengthen portfolio with steady cadence of new product approvals ABBOTT PARK, Ill., Jan. 25, 2023 /PRNewswire/ — Abbott […]
MINNEAPOLIS–(BUSINESS WIRE)–Imricor Medical Systems, Inc. (ASX:IMR) Imricor, the global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation products, is pleased to announce that it has entered into a Memorandum of Understanding (MOU) with GE HealthCare. Under the terms of the MOU, GE HealthCare and Imricor intend to collaborate to interface […]
Treatment IDE Will Provide Opportunity to Treat Additional Patients in the US SAN RAMON, Calif., Jan. 24, 2023 /PRNewswire/ — BioVentrix®, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process of progressive heart […]
tenacio’s OptiCor™ Clinical Decision Support Tool is an easy-to-use tool for clinicians to optimize treatment for patients with atrial fibrillation OptiCor™ has shown significant reductions in mortality and stroke in a previously published study1 BERLIN and NEW YORK, Jan. 24, 2023 /PRNewswire/ — tenacio, whose mission is to improve clinical outcomes for cardiovascular patients and to […]
FDA-cleared and clinically-validated app lets Venu 2 Plus customers record an ECG and check for signs of atrial fibrillation right from their smartwatch OLATHE, Kan., Jan. 24, 2023 /PRNewswire/ — Garmin (NYSE: GRMN) today announced the ECG App1, an FDA-cleared app for the Venu® 2 Plus smartwatch that allows users to record their heart rhythm and check […]
– HAVs observed to provide long-term perfusion to patients with critical limb ischemia – 3D Angiograms show mechanical durability of engineered human blood vessels DURHAM, N.C., Jan. 24, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue […]
Senior Medical Technology Executive to Enhance Company’s Strategic and Operations Capabilities SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, announced today the appointment of Robert Eno to the newly created position […]
